{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:02:35Z","timestamp":1785769355400,"version":"3.56.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,8,2]]},"abstract":"<jats:p>Background: Studies on plasma orexin-A levels in prodromal dementia with Lewy bodies (DLB) and the relationship with clinical manifestations are rare. Objective: To assess plasma orexin-A levels and evaluate the correlation with clinical features in patients with mild cognitive impairment with Lewy bodies (MCI-LB) and DLB. Methods: Plasma orexin-A levels were measured in 41 patients with MCI-LB, 53 with DLB, and 48 healthy controls (HCs). Informant-based history, neurological examinations, neuropsychological assessments, laboratory tests, and neuroimaging were collected and the correlation between orexin-A and various indicators evaluated. Results: Plasma orexin-A levels in patients with MCI-LB (1.18\u00b10.33\u200ang\/mL, p\u200a=\u200a0.014) or DLB (1.20\u00b10.44\u200ang\/mL, p\u200a=\u200a0.011) were significantly higher than in HCs (1.02\u00b10.32\u200ang\/mL) and associated with gender and age. DLB patients with fluctuating cognition (FC) (1.01\u00b10.23 versus 1.31\u00b10.50, p\u200a=\u200a0.007) or parkinsonism (PARK) (0.98\u00b10.19 versus 1.25\u00b10.47, p\u200a=\u200a0.030) had significantly lower plasma orexin-A levels than subjects without FC or PARK. Plasma orexin-A levels were significantly negatively correlated with irritability and UPDRS-III scores and significantly positively correlated with disinhibition scores. Conclusion: This is the first report in which elevated plasma orexin-A levels were observed in patients with MCI-LB or DLB. In addition, lower orexin-A levels were found in patients with DLB and FC or PARK compared with HCs. The plasma orexin-A levels were associated with the presence of core features and motor and neuropsychiatric symptoms in patients with MCI-LB and DLB.<\/jats:p>","DOI":"10.3233\/jad-220082","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T13:23:49Z","timestamp":1655213029000},"page":"1037-1048","source":"Crossref","is-referenced-by-count":11,"title":["Elevated Plasma Orexin-A Levels in Prodromal Dementia with Lewy Bodies"],"prefix":"10.1177","volume":"88","author":[{"given":"Jinghuan","family":"Gan","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Dementia Institute, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Yang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Meng","sequence":"additional","affiliation":[{"name":"Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Dementia Institute, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Aviation General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Department of Neurology, Tianjin Dementia Institute, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220082_ref1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-220082_ref2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","article-title":"Are dementia with Lewy bodies and Parkinson\u2019s disease dementia the same disease","volume":"16","author":"Jellinger","year":"2018","journal-title":"BMC Med"},{"key":"10.3233\/JAD-220082_ref3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/brain\/awm090","article-title":"Hypocretin (orexin) loss in Parkinson\u2019s disease","volume":"130","author":"Fronczek","year":"2007","journal-title":"Brain"},{"key":"10.3233\/JAD-220082_ref4","doi-asserted-by":"crossref","first-page":"765701","DOI":"10.3389\/fendo.2021.765701","article-title":"Orexin-A in patients with Lewy body disease: A systematic review and meta-analysis","volume":"12","author":"Gan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.3233\/JAD-220082_ref5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/WNR.0b013e32833bfb7c","article-title":"Reduced hypocretin (orexin) levels in dementia with Lewy bodies","volume":"21","author":"Lessig","year":"2010","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-220082_ref6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/psyg.12618","article-title":"Association between cerebrospinal fluid Orexin A level and severity of rapid eye movement sleep behaviour disorder in dementia with Lewy bodies","volume":"21","author":"Inagawa","year":"2021","journal-title":"Psychogeriatrics"},{"key":"10.3233\/JAD-220082_ref7","doi-asserted-by":"crossref","first-page":"135480","DOI":"10.1016\/j.neulet.2020.135480","article-title":"Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson\u2019s disease patients.","volume":"741","author":"Huang","year":"2021","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-220082_ref8","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/brain\/awp263","article-title":"Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson\u2019s disease dementia","volume":"132","author":"Compta","year":"2009","journal-title":"Brain"},{"key":"10.3233\/JAD-220082_ref9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-220082_ref10","doi-asserted-by":"crossref","first-page":"724990","DOI":"10.3389\/fnagi.2021.724990","article-title":"Association of elevated plasma total homocysteine with dementia with Lewy bodies: A case-control study","volume":"13","author":"Zhang","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-220082_ref11","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1080\/13607863.2020.1817311","article-title":"Neuropsychiatric profiles in mild cognitive impairment with Lewy bodies","volume":"25","author":"Liu","year":"2021","journal-title":"Aging Ment Health"},{"key":"10.3233\/JAD-220082_ref12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/mds.27997","article-title":"Prodromal dementia with Lewy bodies: Clinical characterization and predictors of progression","volume":"35","author":"van de Beek","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-220082_ref13","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.3233\/JAD-220082_ref14","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-220082_ref15","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1007\/s00415-016-8285-y","article-title":"National validation and proposed revision of REM sleep behavior disorder screening questionnaire (RBDSQ)","volume":"263","author":"Marelli","year":"2016","journal-title":"J Neurol"},{"key":"10.3233\/JAD-220082_ref16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1192\/bjp.177.3.252","article-title":"The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia","volume":"177","author":"Walker","year":"2000","journal-title":"Br J Psychiatry"},{"key":"10.3233\/JAD-220082_ref17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neulet.2014.03.020","article-title":"Neuropathological investigation of hypocretin expression in brains of dementia with Lewy bodies","volume":"569","author":"Kasanuki","year":"2014","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-220082_ref18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000079749","article-title":"Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness","volume":"52","author":"Baumann","year":"2004","journal-title":"Eur Neurol"},{"key":"10.3233\/JAD-220082_ref19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2006.08.004","article-title":"CSF orexin levels of Parkinson\u2019s disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration","volume":"250","author":"Yasui","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-220082_ref20","doi-asserted-by":"crossref","first-page":"fcab050","DOI":"10.1093\/braincomms\/fcab050","article-title":"Pre-treatment of blood samples reveal normal blood hypocretin\/orexin signal in nlepsy type 1","volume":"3","author":"\u00c6gidius","year":"2021","journal-title":"Brain Commun"},{"key":"10.3233\/JAD-220082_ref21","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/schbul\/sbab042","article-title":"Changes of hypocretin (orexin) system in schizophrenia: From plasma to brain","volume":"47","author":"Lu","year":"2021","journal-title":"Schizophr Bull"},{"key":"10.3233\/JAD-220082_ref22","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1212\/WNL.54.8.1616","article-title":"Quantifying fluctuation in dementia with Lewy bodies, Alzheimer\u2019s disease, and vascular dementia","volume":"54","author":"Walker","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JAD-220082_ref23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuron.2012.09.012","article-title":"Neuromodulation of brain states","volume":"76","author":"Lee","year":"2012","journal-title":"Neuron"},{"key":"10.3233\/JAD-220082_ref24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuron.2017.01.014","article-title":"Neural circuitry of wakefulness and sleep.","volume":"93","author":"Scammell","year":"2017","journal-title":"Neuron"},{"key":"10.3233\/JAD-220082_ref25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/01.WNL.0000078194.53210.48","article-title":"Low levels of ventricular CSF orexin\/hypocretin in advanced PD","volume":"61","author":"Drouot","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JAD-220082_ref26","doi-asserted-by":"crossref","first-page":"8435","DOI":"10.1007\/s12035-019-01682-x","article-title":"Early sociability and social memory impairment in the A53T mouse model of Parkinson\u2019s disease are ameliorated by chemogenetic modulation of orexin neuron activity","volume":"56","author":"Stanojlovic","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-220082_ref27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/ijms22020795","article-title":"Inhibition of orexin\/hypocretin neurons ameliorates elevated physical activity and energy expenditure in the A53T mouse model of Parkinson\u2019s disease","volume":"22","author":"Stanojlovic","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-220082_ref28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13041-019-0514-8","article-title":"Pharmacological and chemogenetic orexin\/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson\u2019s disease","volume":"12","author":"Stanojlovic","year":"2019","journal-title":"Mol Brain"},{"key":"10.3233\/JAD-220082_ref29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neulet.2014.07.014","article-title":"Neuroprotection by Orexin-A via HIF-1\u03b1 induction in a cellular model of Parkinson\u2019s disease","volume":"579","author":"Feng","year":"2014","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-220082_ref30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fnins.2018.00835","article-title":"Orexin-A exerts neuroprotective effects via OX1R in Parkinson\u2019s disease","volume":"12","author":"Liu","year":"2018","journal-title":"Front Neurosci"},{"key":"10.3233\/JAD-220082_ref31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/bc.bc_42_19","article-title":"Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review","volume":"6","author":"Al-Kuraishy","year":"2020","journal-title":"Brain Circ"},{"key":"10.3233\/JAD-220082_ref32","doi-asserted-by":"crossref","first-page":"711350","DOI":"10.3389\/fnsys.2021.711350","article-title":"Thalamo-nucleus accumbens projections in motivated behaviors and addiction","volume":"15","author":"De","year":"2021","journal-title":"Front Syst Neurosci"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:23Z","timestamp":1777370783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":32,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-220082","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]}}}